Cell, Heal

A New Form of Medicines

Novel class drugs, Revolutionary medicines Use the power of cells, the basic unit of life

Vision

We envision a world that cancer is no longer a devastating disease, because of collective efforts including ours to develop better medicines.

Latest News

The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,891,628 entitled, “Method for biomimetic culture of urothelial cells and uses thereof.” invented by co-founders Drs. Chih-Rong, Shyr and Chih-Ping Huang on February 6, 2024. This patent owned by eXCELL Biotherapeutics INC. is a breakthrough xenogeneic cell-based therapy for treating bladder cancer by harnessing the body’s immune system. The Japanese Patent has been published on 19 December. Patent No. 7272676 on May 1, 2023. Chinese Patent and Taiwan Patent are still pending. This patent family owned by eXCELL demonstrates the company's pioneering and leading role in xenogeneic cell cancer immunotherapy field.

Mission

To discover, develop, and deliver transformative xenogeneic cellular medicines to cancer patients and improve their outcomes. eXCELL is a company dedicated to developing revolutionary therapies to meliorate people’s lives.

Our Team

作者石志榮照片

Product Development

Co-Founder

Chih-Rong Shyr Ph.D.

CEO, eXCELL Biotherapeutics

Clinical Development

Co-Founder

Chi-Ping, Huang M.D.

Director of Urology, Division,

China Medical University Hospital

Dr 劉志良

Clinical Development

Co-Founder

Liang-Chih, Liu M.D.

Director of Breast Surgical, Oncology,

China Medical University Hospital

The eXCELL team is comprised of leading scientists and physician who are dedicated to realizing the potential of cellular medicines to constructively restore and revive the body functions and reverse the courses of cancer progression, delivering the impactful therapies to change the patient outcomes. eXCELL is a leading biotechnology specialized in immunotherapy company developing transformative therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell and B cell) immune systems to create long-term “immunological memory.” through the built-in rejection immune response to non-self cells.
作者石志榮照片

CEO & CO-FOUNDER

To discover, develop, and deliver transformative cellular medicines to cancer patients and improve their outcomes. eXCELL is a company dedicated to developing revolutionary therapies to meliorate people’s lives.

eXCELL is an immunotherapy company that uses the body built-in immune rejection responses to non-self cells to combat the difficult-to-treat cancers by utilizing xenogeneic cells that could promote cancer immunity cycle due to the similarities between xenogeneic cells and tumor cells.

 

 

Constructive ways to treat cancers

Current cancer treatments (surgery, radiotherapy, chemotherapy and targeted therapy) that use physical forces and chemical and biological inhibitors are destructive.

Although effective in early-stage cancers, the treatments also cause damages to normal tissues and most advanced cancers eventually become resistant, resulting in excruciating death with toxic treatments.

Combination of therapy has the possibility to solve the complex of cancer, However adding more destructive treatments also further damage the body. On the other hand, xenogeneic cell therapy is a constructive way to treat diseases using the properties of cells in the body to reprogram the immune system and physiological functions, providing potential new constructive options for patients with this difficult-to-treat cancers. Constructive treatments will lessen the side effects, but increase efficacy of the combined treatment to transform the way we treat cancers.

With the combination of destructive and constructive treatments, patients receive a comprehensive cancer management that would enhance quality of life and survival of patients significantly. Locoregional xenogeneic tissue-specific cell immunotherapy completes the comprehensive cancer treatment.